In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
  • Year

    Select Year(s)

  • Session Type

    Select Session Type(s)

  • Resource type

    Select Resource type(s)

  • Topic

    Select Topic(s)

Filters (0)
  • sub-topic
  • Year
  • Session Type
  • Resource type
  • Topic
  • sub-topic
  • Year
  • Session Type
  • Resource type
  • Topic

Sponsored content

Presentations below are part of sessions sponsored by Bayer

115 results for your search

A holistic approach to cardiovascular protection with rivaroxaban.

Congress : ESC Congress 2018

  • Session : Rivaroxaban in cardiovascular protection - Getting to the heart of the matter
  • Speaker : A Kakkar (London,GB)
  • Sponsored by Bayer AG

A new era in the management of atherosclerotic disease: vascular protection and the COMPASS trial.

Congress : Heart Failure 2018

  • Session : Expanding the evidence in heart failure patients
  • Speaker : M R Cowie (London,GB)
  • Sponsored by Bayer AG

A paradigm shift becoming reality.

Congress : ESC Congress 2018

  • Session : Setting the COMPASS into new directions
  • Speaker : S Yusuf (Hamilton,CA)
  • Sponsored by Bayer AG

CAD patients with concomitant Heart Failure (HF): are current treatments enough?

Congress : Heart Failure 2018

  • Session : Expanding the evidence in heart failure patients
  • Speaker : B Pieske (Berlin,DE)
  • Sponsored by Bayer AG

Cardiovascular protection: your questions answered.

Congress : ESC Congress 2018

  • Session : Rivaroxaban in cardiovascular protection - Getting to the heart of the matter
  • Speaker : A J Camm (London,GB), R Welsh (Edmonton,CA)
  • Sponsored by Bayer AG

Closing Remarks - Managing pulmonary embolism according to patient profile in the NOAC era.

Congress : ESC Congress 2018

  • Session : Managing pulmonary embolism according to patient profile in the NOAC era
  • Speaker : S V Konstantinides (Mainz,DE)
  • Sponsored by Bayer AG

Closing remarks - New directions in antithrombotic management of high risk patients.

Congress : ESC Congress 2018

  • Session : New directions in antithrombotic management of high risk patients
  • Speaker : M R Cowie (London,GB)
  • Sponsored by Bayer AG

Closing remarks - New directions in the management of thrombotic risks in patients with heart failure.

Congress : ESC Congress 2018

  • Session : New directions in the management of thrombotic risks in patients with heart failure
  • Speaker : F Zannad (Vandoeuvre Les Nancy,FR)
  • Sponsored by Bayer AG

Closing remarks - Rivaroxaban in cardiovascular protection - Getting to the heart of the matter.

Congress : ESC Congress 2018

  • Session : Rivaroxaban in cardiovascular protection - Getting to the heart of the matter
  • Speaker : A J Camm (London,GB)
  • Sponsored by Bayer AG

Closing remarks - Rivaroxaban in cardiovascular protection - Getting to the heart of the matter.

Congress : ESC Congress 2018

  • Session : Rivaroxaban in cardiovascular protection - Getting to the heart of the matter
  • Speaker : A J Camm (London,GB)
  • Sponsored by Bayer AG

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are